Aktis Oncology Inc.
AKTS evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Market Cap:
- $1.34B
- Lead Asset:
- [225ac]ac-aky-1189 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for AKTS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AKTS
Aktis Oncology Inc. (AKTS) is a clinical-stage biotechnology company developing targeted alpha-particle radiopharmaceuticals, primarily using actinium-225, for the treatment of solid tumors, with lead programs targeting Nectin-4 and B7-H3.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.34B
Cash Runway
—
Lead Asset
[225ac]ac-aky-1189 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for Aktis Oncology Inc..
Aktis Oncology Inc. (AKTS) is a clinical-stage biotechnology company developing targeted alpha-particle radiopharmaceuticals, primarily using actinium-225, for the treatment of solid tumors, with lead programs targeting Nectin-4 and B7-H3.
- Cash & equivalents of $82.5M as of 2026-06-30 [sec].
- Total revenue of $3.4M and net income of -$24.1M for the six months ended June 30, 2026 [sec].
- Accumulated deficit of $199.0M as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Lead product candidate [225Ac]Ac-AKY-1189 (Nectin-4) initiated Phase 1b trial NECTINIUM-2 on 2025-08-22 [catalyst].
- Second product candidate [225Ac]Ac-AKY-2519 (B7-H3) initiated Phase 1b trial BActinium-1 on 2026-06-17 [catalyst].
What works
- Two product candidates have advanced into Phase 1b clinical trials: [225Ac]Ac-AKY-1189 for Nectin-4 expressing tumors and [225Ac]Ac-AKY-2519 for B7-H3 expressing tumors [catalyst].
- The company has a cash position of $82.5M as of 2026-06-30, providing a runway to support ongoing clinical and preclinical activities [sec].
- Aktis is developing a proprietary miniprotein radioconjugate platform, which may enable targeting of novel epitopes [sec_mda · as of 2026-08-13].
What to weigh
- The company has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-08-13].
- Net losses are increasing: $63.7M in FY2025, $33.1M in H1 2025, and $42.5M in H1 2026 [sec_mda · as of 2026-08-13].
- Accumulated deficit has grown to $199.0M as of June 30, 2026, and expenses are expected to increase substantially as clinical programs advance [sec_mda · as of 2026-08-13].
- The company has a limited operating history (founded August 2020) and will require additional funding to finance operations [sec_mda · as of 2026-03-30].
From the filings
Quoted directly from source documents.
Lead candidate [225Ac]Ac-AKY-1189 Phase 1b start date
“Phase1_Start: NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors”
Catalysts · August 22, 2025
Second candidate [225Ac]Ac-AKY-2519 Phase 1b start date
“Phase1_Start: BActinium-1: A Phase 1b, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Intravenous Administration of B7-H3 Radiopharmaceutical ([225Ac]Ac-AKY-2519) in Metastatic Castration-Resistant Prostate Cancer”
Catalysts · June 17, 2026
Accumulated deficit as of June 30, 2026
“2026, we had an accumulated deficit of $199.0 million”
SEC MD&A · August 13, 2026
No products approved for sale and no revenue from product sales
“We do not have any products approved for sale and have not generated any revenue from product sal”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2025-08-22 · Phase1_Start: NECTINIUM-2 ([225Ac]Ac-AKY-1189) — Initiation of Phase 1b trial for Nectin-4 radiopharmaceutical in advanced solid tumors.
- 2026-06-17 · Phase1_Start: BActinium-1 ([225Ac]Ac-AKY-2519) — Initiation of Phase 1b trial for B7-H3 radiopharmaceutical in metastatic castration-resistant prostate cancer.
Risks & what to watch (4)›
Key risks
- No approved products — No products approved for sale; no revenue from product sales; entirely dependent on future clinical success [sec_mda · as of 2026-08-13].
- Increasing net losses — Net losses grew from $44.0M (FY2024) to $63.7M (FY2025) and $42.5M in H1 2026 alone [sec_mda · as of 2026-08-13].
- Need for additional capital — Company expects expenses to increase substantially and will require additional funding; failure to raise capital could delay or eliminate programs [sec_mda · as of 2026-03-30].
- Limited operating history — Founded August 2020; limited track record makes evaluation of prospects difficult; may face unforeseen expenses and delays [sec_mda · as of 2026-03-30].
What to watch
- Progress of Phase 1b trial NECTINIUM-2 for [225Ac]Ac-AKY-1189 (Nectin-4) initiated 2025-08-22 [catalyst].
- Progress of Phase 1b trial BActinium-1 for [225Ac]Ac-AKY-2519 (B7-H3) initiated 2026-06-17 [catalyst].
- Cash burn rate and timing of next financing round given $82.5M cash as of 2026-06-30 and increasing operating losses [sec].
- Regulatory updates for IND-enabling preclinical studies of other pipeline programs [sec_mda · as of 2026-08-13].
Sources: Catalysts · SEC MD&A · Generated October 5, 2026 · How we verify sources →
Run Aktis Oncology Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aktis Oncology Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.15 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
0 buys · 9 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 16.3%
- Days to cover
- 8.1
- Shares short
- 2,570,690
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AKTS short interestFrequently asked questions
What is the AI investment thesis for Aktis Oncology Inc.?
Aktis Oncology Inc. (AKTS) is a clinical-stage biotechnology company developing targeted alpha-particle radiopharmaceuticals, primarily using actinium-225, for the treatment of solid tumors, with lead programs targeting Nectin-4 and B7-H3.
What is Aktis Oncology Inc.'s lead drug candidate?
Aktis Oncology Inc.'s most advanced tracked candidate is [225ac]ac-aky-1189 (Phase 1) for Urothelial Carcinoma Bladder.
Who is the CEO of Aktis Oncology Inc.?
Dr. Matthew Roden Ph.D. is the chief executive officer of Aktis Oncology Inc. (AKTS).
Where is Aktis Oncology Inc. headquartered?
Aktis Oncology Inc. (AKTS) is headquartered in Boston, MA, United States.
What therapeutic areas does Aktis Oncology Inc. focus on?
Aktis Oncology Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.